Table 1.

Characteristics of the 26 patients in the phase II trial

CharacteristicNumber (%)
Gender
 Female10 (38)
 Male16 (62)
Stage
 IIIB11 (42)
 IIIC12 (46)
 IV3 (12)
Mutation status
 BRAF V600E4 (15)
 NRAS9 (35)
 WT9 (35)
 Unknown4 (15)
Melanoma subtype
 Acral3 (12)
 Cutaneous19 (73)
 Unknown primary4 (15)
High tumor burden
(>50 lesions or one >3 cm)
 Yes7 (27)
 No19 (73)